综述 Review

霍奇金淋巴瘤的治疗策略分析及研究进展

Published at: 2015年第35卷第6期

刘勇 1 , 杨海玉 2
1 江西省人民医院病理科,南昌 330006
2 江西省人民医院临床医学研究所,南昌 330006
通讯作者 海玉 杨 Email: yanghaiyu@yahoo.com
DOI: 10.3978/j.issn.2095-6959.10.3978/j.issn.2095-6959.2015.06.059
基金:

摘要

霍奇金淋巴瘤(Hodgkin’s lymphoma,HL)是一种病因不明的B细胞恶性肿瘤,包括经典型HL和结节性淋巴细胞型HL。为了提高治疗效果和改善病人预后,目前认为针对不同病变分期的HL病人宜采取不同的治疗策略。早期病人主要采用联合物理治疗的方法,通常是短时程联合化疗加低剂量受累淋巴结局部放疗(involved-field radiation therapy,IFRT)。进展期病人建议接受较长时程化疗或增强化疗,但应尽可能减少治疗毒性反应的发生。高剂量化疗加自体干细胞移植(autologous stem cell transplant,ASCT)是目前多数复发/难治性HL病人的标准治疗方法,但ASCT治疗失败后仍然缺乏十分有效的治疗手段。未来研究方向是将更多有效的新型药物整合到一线治疗方案中,进一步提高HL病人的生存预后并减少并发症的发生。


The treatment strategy of Hodgkin’s lymphoma and its advanced research

Abstract

Hodgkin’s lymphoma (HL) is a kind of B-cell lymphoid malignancies and the cause of HL remains unknown. HL is composed of two distinct disease entities, including classical HL and nodular lymphocyte-predominant HL. In order to improve the treatment effect and patients prognosis, patients with HL in different stages of disease should take different treatment strategies. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy (IFRT), while those with advanced stage disease receive a longer course of chemotherapy or escalated therapy and should minimize treatment toxicity reaction. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients with relapsed/refractory HL. However, there is still lack of effective drugs for patients who fail with ASCT. The future research direction is to integrate more effective new drugs into the first-line treatment scheme for improving the survival of patients and reducing complications.


comments powered by Disqus

全文

引用

引用本文: 勇 刘, 海玉 杨. 霍奇金淋巴瘤的治疗策略分析及研究进展[J]. 临床与病理杂志, 2015, 35(6): 1180-1183.
Cite this article as: LIU Yong, YANG Haiyu . The treatment strategy of Hodgkin’s lymphoma and its advanced research[J]. Journal of Clinical and Pathological Research, 2015, 35(6): 1180-1183.